Katy Beckermann, M.D., Ph.D., Merck FellowVanderbilt University

CRI’s financial support is greatly appreciated - allowing me to focus on basic science and translational work asking questions we see in the clinic and trying to understand why they happen in the lab.
Area of Research: Breast Cancer, Lung Cancer, Melanoma, Kidney Cancer

Glucose is an important energy source for our cancer-killing T cells. In kidney tumors, however, poor nutrient conditions often disrupt T cell metabolism and inhibit their anti-cancer activity. Dr. Beckermann is characterizing how exactly the tumor environment perturbs T cell metabolism. Then, using patients’ cells and mouse models, she’s developing approaches to support T cells and restore their normal metabolism. The insights she uncovers might then suggest ways to target and improve the effectiveness of these anti-cancer T cells in immunotherapies for patients.

Katy Beckermann, CRI-Funded Scientist: i love my job. there are days when I take care of patients in the clinic, who are undergoing treatment for their cancer. I'm motivated knowing that my research may improve their therapy.

Projects and Grants

Metabolic barriers to T cell function and immunotherapy in renal cell carcinoma

Vanderbilt University | Breast Cancer, Kidney Cancer, Lung Cancer, Melanoma | 2016 | Jeffrey Rathmell, Ph.D.

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.